Erratum: Effect of silencing PARG in human colon carcinoma LoVo cells on the ability of HUVEC migration and proliferation

Correction to: Cancer Gene Therapy (2012) 19, 715–722; doi:10.1038/cgt.2012.48; published online 24 August 2012

Figures 1 and 2 in this article were published with errors. The correct figure parts, and their legends, are reproduced correctly here. The authors regret the errors.

Figure 1

(a) LoVo cells transfected with TurboGFP ( × 400). In all, 2, 5, 10 and 15 μl of lentiviral particles containing TurboGFP were transfected into LoVo cells. After 48 h of incubation at 37 °C fluorescin was displayed in LoVo cells. (A) Represents 2 μl of lentiviral particles containing the TurboGFP group, (B) 5, (C) 10 and (D) 15 μl. (d and f) Effect of knockdown PARG by shRNA in LoVo cells. RT-PCR reveals complete inhibition of PARG expression in PARG-shRNA-transfected cells compared with untransfected and control-shRNA cells. β-Actin was used as an internal loading control.

Figure 2

(c and d) Western blot analysis highlights a decrease in expression of cytoplasmic p-IκBα together with a fall in the intranuclear expression of NFκ-B in PARG-shRNA cells compared with both untransfected and control-shRNA cells (*P<0.05).